Tabrecta (capmatinib) Patient Assistance Program
Don’t let the high cost of brand MET inhibitor disrupt your MET exon 14 skipping NSCLC treatment. We help eligible patients access Tabrecta (capmatinib tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Tabrecta (capmatinib) is FDA-approved for treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping. Selective MET kinase inhibitor. Precision oncology therapy based on molecular biomarker (MET exon 14 skipping mutation — ~3% of NSCLC).
- Without assistance, Tabrecta costs commonly run approximately $18,000+ per month.
- Through AffordMyPrescriptions, qualifying patients can access Tabrecta for a flat $69.95 per month.
- Other MET-targeted therapies for NSCLC: tepotinib (Tepmetko — brand; similar MET exon 14 skipping indication). Emrelis (telisotuzumab vedotin — anti-c-Met ADC for c-Met protein overexpression; different biomarker). Other NSCLC targeted therapies: osimertinib (Tagrisso — EGFR), alectinib/Alecensa, crizotinib, lorlatinib (ALK), entrectinib/Rozlytrek, larotrectinib/Vitrakvi (NTRK), dabrafenib+trametinib (BRAF V600E), sotorasib/Lumakras or adagrasib/Krazati (KRAS G12C), pralsetinib/Gavreto (RET). Comprehensive NGS testing essential for advanced NSCLC.
What is Tabrecta Prescription Assistance Program?
The Tabrecta Patient Assistance Program helps eligible patients access this MET inhibitor at little or no cost when meeting income, insurance, and clinical criteria. Free to apply but involves detailed applications, oncology coordination, MET exon 14 biomarker documentation, and renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Tabrecta PAP enrollment for a flat $69.95 per month — so you never face a gap in Tabrecta NSCLC therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Tabrecta enrollment — so you never face a gap in your MET exon 14 skipping NSCLC treatment.
Pharmacy Price Comparison
- Without assistance, Tabrecta costs thousands per month at specialty pharmacies. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Specialty pharmacy | ~$18,000/mo | Save substantially |
| Walgreens Specialty | ~$19,000/mo | Save substantially |
| CVS Specialty | ~$20,000/mo | Save substantially |
| 340B-eligible institution | ~$15,000/mo | Save substantially |
| Tepmetko (alt MET inhibitor) | ~$18,000/mo | Alt MET inhibitor |
| Docetaxel generic (chemo) | ~$500/cycle | Generic chemo alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Tabrecta — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Tabrecta Prescription Program?
The Tabrecta Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Comprehensive NGS molecular testing essential for NSCLC — MET exon 14 skipping plus many other actionable mutations (EGFR, ALK, ROS1, BRAF, KRAS G12C, HER2, RET, NTRK, others).
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Tabrecta assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Tabrecta is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Tabrecta:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $18,000+ per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Tabrecta assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Tabrecta Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Tabrecta:
Tabrecta is a selective MET kinase inhibitor for MET exon 14 skipping mutation-positive metastatic NSCLC. Precision oncology built on validated biomarker — MET exon 14 skipping mutations occur in ~3% of NSCLC.
How It Works:
MET (mesenchymal-epithelial transition factor) is a receptor tyrosine kinase. MET exon 14 skipping mutations disrupt the juxtamembrane domain responsible for MET ubiquitination and degradation — leads to sustained MET signaling driving oncogenesis. Occurs in ~3% of NSCLC (higher rate in older non-smokers with sarcomatoid features). Testable via NGS. Capmatinib is a highly selective ATP-competitive MET kinase inhibitor. Blocks MET signaling in MET exon 14 skipping mutant NSCLC. Alternative MET inhibitor: tepotinib (Tepmetko) — similar mechanism and indication. Distinct from Emrelis (telisotuzumab vedotin — anti-c-Met ADC for c-Met protein overexpression, a different biomarker). MET amplification (elevated MET copy number) is a separate biomarker; MET inhibitors have activity in some MET-amplified NSCLC but efficacy less established than in MET exon 14 skipping.
Form and Use:
Tabrecta tablets 150 mg, 200 mg. 400 mg twice daily with or without food. Continue until disease progression or unacceptable toxicity. Requires MET exon 14 skipping mutation testing.
Generic Availability:
No generic Tabrecta. Similar MET inhibitor: tepotinib (Tepmetko — brand; MET exon 14 skipping mutation NSCLC). Different biomarker: Emrelis (telisotuzumab vedotin — anti-c-Met ADC for c-Met protein overexpression). Other NSCLC targeted therapies (all brand): osimertinib (Tagrisso — EGFR), alectinib (Alecensa)/lorlatinib (Lorbrena)/crizotinib (Xalkori) — ALK, entrectinib (Rozlytrek)/larotrectinib (Vitrakvi) — NTRK/ROS1, dabrafenib (Tafinlar) + trametinib (Mekinist) — BRAF V600E, sotorasib (Lumakras)/adagrasib (Krazati) — KRAS G12C, pralsetinib (Gavreto) — RET, others. First-line for non-actionable NSCLC: platinum chemotherapy + immunotherapy (Keytruda most common) ± targeted addition. Comprehensive NGS molecular testing essential. LUNGevity Foundation resources.
Warnings:
Interstitial lung disease/pneumonitis (potentially fatal — monitor respiratory symptoms and imaging; permanent discontinuation for confirmed ILD/pneumonitis), hepatotoxicity (elevated LFTs — monitor; can be severe), pancreatic toxicity (lipase/amylase elevation), photosensitivity (avoid direct sunlight), embryo-fetal toxicity (contraindicated in pregnancy). Other: peripheral edema, nausea, fatigue, vomiting, dyspnea, decreased appetite, back pain. Drug interactions: CYP3A4 substrate (avoid strong inhibitors/inducers), P-gp interactions. Photoprotection important.
FAQ (Frequently Asked Questions)
How much does Tabrecta cost without insurance?
$18,000+ per month at specialty pharmacies. Tepmetko (tepotinib — alternative MET inhibitor) similarly priced. Patient Assistance Programs essential.
How is Tabrecta different from Tepmetko?
Both are selective MET kinase inhibitors for MET exon 14 skipping mutation NSCLC. Similar mechanism and indications. Both effective. Choice depends on clinical trial data preference, side effect profile considerations, and access.
How is Tabrecta different from Emrelis?
Different biomarkers and mechanisms. Tabrecta targets MET exon 14 skipping mutation via selective MET kinase inhibition — small molecule oral. Emrelis (telisotuzumab vedotin) targets c-Met protein overexpression via antibody-drug conjugate — IV infusion. Different subsets of NSCLC. Molecular testing determines which applies.
Do I need molecular testing before Tabrecta?
Yes — Tabrecta requires MET exon 14 skipping mutation testing. Comprehensive NGS of NSCLC is standard-of-care — identifies multiple actionable mutations (EGFR, ALK, ROS1, BRAF, KRAS G12C, HER2, RET, MET exon 14, NTRK). Molecular testing informs precision therapy selection.
How long is Tabrecta therapy?
Continue until disease progression or unacceptable toxicity, per standard oncology practice. Response assessment by imaging every 8–12 weeks. Discuss expectations with your oncologist.
Take Control of Your Medication Costs
Precision therapy for MET exon 14 skipping NSCLC offers targeted treatment for a rare actionable mutation. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.